Discover Diabetes

THE DISCOVER STUDY

  • A global observational study of patients with type 2 diabetes mellitus who are starting second-line glucose-lowering therapy.
  1. HOME
  2. News and views
  3. Baseline glycaemic control
Menu
  • HOME
  • News and views
    • DISCOVER Study and Registry
    • Treatment patterns in global DISCOVER population
    • Baseline glycaemic control
    • Discover SC Meeting
  • The DISCOVER study
  • Diabetes and real world evidence
  • DISCOVER Publications
    • redirect-to-post-event-244-posters-77790
  • studylocation
  • DISCOVER PUBLICATIONS PROPOSALS
  • DISCOVER-study-old

Baseline glycaemic control in the DISCOVER population

10/17/19

We are pleased to announce that an article analysing glycaemic control in patients enrolled in the DISCOVER study titled ‘Glycaemic control in patients with type 2 diabetes initiating second-line therapy: results from the global DISCOVER study programme’ has now been published in Diabetes, Obesity and Metabolism.1

The article describes the glycated haemoglobin (HbA1c) levels in patients enrolled in DISCOVER from 37 countries across six continents at the initiation of second-line therapy (baseline), and the clinical and socioeconomic factors that were found to be associated with poor glycaemic control (defined as HbA1c levels > 8.0%).

Overall, baseline HbA1c level data were available for 80.9% of the patients enrolled in the study, with substantial regional variation in the proportion of patients with recorded baseline HbA1c levels (across region range [ARR]: 57.5–98.2%). The overall mean HbA1c level among these patients was 8.3% (ARR: 7.9–8.7%; Figure 1). More than 50.0% of the patients had an HbA1c level ≥ 8.0%, and more than 25.0% of patients had an HbA1c level ≥ 9.0%. Factors associated with poor baseline glycaemic control included living in a lower-middle-income country (versus living in a high-income country), a longer duration of type 2 diabetes and a lower education level.

The full article is available to read and download here!

Keywords:
Average User Rating
No ratings yet - be the first

Add your Rating

Thank you!

Edit your Rating

anonymous
/content/PhysicianServices/global/387-discoverdiabetes-com/en/en/news-views/Baseline-glycaemic-control
Baseline-glycaemic-control
Share

Only Logged-In users can view this link!

Invalid Email

To:

For multiple recipients, Enter comma seperated email addresses.

E-mail

Your message has been sent successfully

Mail send failed

Choose a folder

  • No categories are available

Related Content

No Results

Figure 1. Mean baseline HbA1c level by DISCOVER study region.

Baseline glycaemic control in the DISCOVER population

1. Khunti K et al. Glycaemic control in patients with type 2 diabetes initiating second-line therapy: results from the global DISCOVER study programme. Diabetes Obes Metab 2019; doi:10.1111/dom.13866.

 

 
 
 
 
  • Legal Notice
  • Privacy Notice
  • Cookie Notice
  • © AstraZeneca 2019
  • Contact us
  • Approval ID: Z4-21898
  • Date of preparation: March 2020
  • Date of expiry: March 2021
AZ Logo

The DISCOVER study is sponsored by AstraZeneca